Z-DON-Val-Pro-Leu-Ome| CAS#N/A| specific inhibitor| MedKoo

MedKoo Cat#: 565495 | Name: Z-DON-Val-Pro-Leu-Ome

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Z-DON-Val-Pro-Leu-Ome is a site specific inhibitor of tissue transglutaminase

Chemical Structure

Z-DON-Val-Pro-Leu-Ome

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 565495

Name: Z-DON-Val-Pro-Leu-Ome

CAS#: N/A

Chemical Formula: C31H44N6O8

Exact Mass: 628.3221

Molecular Weight: 628.73

Elemental Analysis: C, 59.22; H, 7.05; N, 13.37; O, 20.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Z-DON; Z DON; ZDON

IUPAC/Chemical Name

Methyl ((S)-2-(((benzyloxy)carbonyl)amino)-6-diazo-5-oxohexanoyl)-L-valyl-L-prolyl-L-leucinate

InChi Key

IWKQKSIBGVYGGD-CQJMVLFOSA-N

InChi Code

InChI=1S/C31H44N6O8/c1-19(2)16-24(30(42)44-5)34-28(40)25-12-9-15-37(25)29(41)26(20(3)4)36-27(39)23(14-13-22(38)17-33-32)35-31(43)45-18-21-10-7-6-8-11-21/h6-8,10-11,17,19-20,23-26H,9,12-16,18H2,1-5H3,(H,34,40)(H,35,43)(H,36,39)/t23-,24-,25-,26-/m0/s1

SMILES Code

CC(C)C[C@@H](C(OC)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@@H](NC(OCC2=CC=CC=C2)=O)CCC(C=[N+]=[N-])=O)=O)=O)CCC1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 628.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Algarni AS, Hargreaves AJ, Dickenson JM. Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth. Eur J Pharmacol. 2018 Feb 5;820:113-129. doi: 10.1016/j.ejphar.2017.12.023. Epub 2017 Dec 11. PubMed PMID: 29242118. 2: Vyas FS, Nelson CP, Dickenson JM. Role of transglutaminase 2 in A(1) adenosine receptor- and β(2)-adrenoceptor-mediated pharmacological pre- and post-conditioning against hypoxia-reoxygenation-induced cell death in H9c2 cells. Eur J Pharmacol. 2018 Jan 15;819:144-160. doi: 10.1016/j.ejphar.2017.11.049. Epub 2017 Dec 5. PubMed PMID: 29208472. 3: Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, Petruccioli E, Goletti D, Rossin F, Piacentini M, Delogu G. Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. J Intern Med. 2018 Mar;283(3):303-313. doi: 10.1111/joim.12714. Epub 2017 Dec 4. PubMed PMID: 29205566. 4: Vyas FS, Nelson CP, Freeman F, Boocock DJ, Hargreaves AJ, Dickenson JM. β(2)-adrenoceptor-induced modulation of transglutaminase 2 transamidase activity in cardiomyoblasts. Eur J Pharmacol. 2017 Oct 15;813:105-121. doi: 10.1016/j.ejphar.2017.07.043. Epub 2017 Jul 25. PubMed PMID: 28754379. 5: Algarni AS, Hargreaves AJ, Dickenson JM. Role of transglutaminase 2 in PAC(1) receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells. Biochem Pharmacol. 2017 Mar 15;128:55-73. doi: 10.1016/j.bcp.2017.01.001. Epub 2017 Jan 5. PubMed PMID: 28065858. 6: Vyas FS, Hargreaves AJ, Bonner PL, Boocock DJ, Coveney C, Dickenson JM. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival. Biochem Pharmacol. 2016 May 1;107:41-58. doi: 10.1016/j.bcp.2016.03.016. Epub 2016 Mar 21. PubMed PMID: 27005940. 7: Almami I, Dickenson JM, Hargreaves AJ, Bonner PL. Modulation of transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: a role for transglutaminase 2 in cytoprotection. Br J Pharmacol. 2014 Aug;171(16):3946-60. doi: 10.1111/bph.12756. PubMed PMID: 24821315; PubMed Central PMCID: PMC4128055. 8: Johnson KB, Petersen-Jones H, Thompson JM, Hitomi K, Itoh M, Bakker EN, Johnson GV, Colak G, Watts SW. Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. Am J Physiol Heart Circ Physiol. 2012 Apr 1;302(7):H1355-66. doi: 10.1152/ajpheart.00918.2011. Epub 2012 Feb 3. PubMed PMID: 22307675; PubMed Central PMCID: PMC3330795.